Cognex (Tacrine) Drug Information: Medication Guide and Patient Information

Pill Identifier Search

May 26, 2012

Cognex

Alzheimer's Disease »

What is dementia?

Dementia is a syndrome characterized by:

impairment in memory,

impairment in another area of thinking such as the ability to organize thoughts and reason, the ability to use language, or the ability to see accurately the visual world (not because of eye disease), and

these impairments are severe enough to cause a decline in the patient's usual level of functioning.

Although some kinds of memory loss are normal parts of aging, the changes due to aging are not severe enough to interfere with the level of function. Many different diseases can cause dementia, but Alzheimer's disease is by far the most common cause for dementia in the United States and in most countries in the world.

What is Alzheimer's disease?

Alzheimer's disease (AD) is a slowly progressive disease of the brain that is characterized by impairment of memory and eventually by dist...

Read the Alzheimer's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Cognex

Dementia Slideshow Pictures

Alzheimer's Disease Slideshow Pictures

Take the Alzheimer's Quiz

font size

PATIENT INFORMATION

Caregivers

Patients and caregivers should be advised that the effect of Cognex® (brand of tacrine hydrochloride) therapy is thought to depend upon its administration at regular intervals, as directed.

The caregiver should be advised about the possibility of adverse effects. Two types should be distinguished: (1) those occurring in close temporal association with the initiation of treatment or an increase in dose (eg, nausea, vomiting, loose stools, diarrhea, etc) and (2) those with a delayed onset (eg, rash, jaundice, changes in the color of stool-black, very dark or light [ie, acholic]).

Patients and caregivers should be encouraged to inform the physician about the emergence of new events or any increase in the severity of existing adverse clinical events. Caregivers should be advised that abrupt discontinuation of Cognex® (tacrine) or a large reduction in total daily dose (80 mg/day or more) may cause a decline in cognitive func-t ion and behavioral disturbances. Unsupervised increases in the dose of tacrine may also have serious consequences. Consequently, changes in dose should not be undertaken in the absence of direct instruction of a physician.

Last reviewed on RxList: 6/24/2008
This monograph has been modified to include the generic and brand name in many instances.